Novartis AG ADR (NVS)vsViatris Inc (VTRS)
NVS
Novartis AG ADR
$148.09
+1.41%
HEALTHCARE · Cap: $286.27B
VTRS
Viatris Inc
$13.36
+0.53%
HEALTHCARE · Cap: $15.20B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 296% more annual revenue ($56.67B vs $14.30B). NVS leads profitability with a 24.7% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$148.09
$99.47 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 24.7% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?